Health Sector Losers – IRIDEX Corporation (NASDAQ:IRIX), Aerie Pharmaceuticals Inc (NASDAQ:AERI), Pro-Dex Inc (NASDAQ:PDEX), Mirati Therapeutics (NASDAQ:MRTX)

IRIDEX Corporation reported preliminary revenues of approximately $10.6 million and $38.3 million for the fourth quarter and full year 2013, respectively. Preliminary revenues in the fourth quarter exceeded the high end of the Company’s guidance and were driven by a continued strong uptick in sales of laser systems both in the U.S. and internationally. Management had projected revenues to be between $10.2 million and $10.5 million in the fourth quarter of 2013. Shares of IRIDEX Corporation (NASDAQ:IRIX) closed at $8.31 in last trading session. Yesterday share price of the company was traded in the range of $8.06 to $9.49. Company now has a market value of $81.48 million. IRIDEX Corporation (NASDAQ:IRIX) price to sales ratio in past twelve months was calculated as 2.04 and price to cash ratio as 5.33.

Needham & Company analyst Elliot Wilbur boosted his price target on Buy-rated Aerie Pharma (NASDAQ: AERI) from $18 to $22 saying today’s data supports more favorable uptake assumptions. Aerie Pharmaceuticals Inc (NASDAQ:AERI) stock traded in the range of $15.03 – $17.06 and at the end of the day, it closed at $15.76. Average trading volume of the company is $111.38M. Aerie Pharmaceuticals Inc (NASDAQ:AERI) return on equity ratio is recorded as 185.10%.

Pro-Dex Potential Inc (NASDAQ:PDEX) Insider Buys Suggest Dramatic Stock Rise, by Valuable Insights. A pending rights offering puts a near-term ceiling on PDEX shares, but improving fundamentals and clear insider interest could signal significant long-term upside. Pro-Dex Inc (NASDAQ:PDEX) after opening at $3.38, moved down -5.91% to $3.17 on last trading day. Company’s 52 week range is $1.80 – $3.80.

Mocetinostat, which is being developed by the pharmaceutical com­pany Mirati Therapeutics (NASDAQ:​MRTX), belongs to a class of drugs known as histone deacetylase (HDAC) inhibitors. These drugs work by increasing the production of proteins that slow cell division and cause cell death. Mirati Therapeutics, Inc. (NASDAQ:MRTX) stock hit highest price at $20.31, beginning with a price of $21.43 and decreased -6.12% to the close at $20.31 with day range of $20.02 – $21.89. The total market capitalization of the stock is $286.92 million.

Leave a Reply